Compounds > pioglitazone
Page last updated: 2024-08-16

pioglitazone and (4-(n-hydroxyamino)-2r-isobutyl-3s-methylsuccinyl)-l-phenylglycine-n-methylamide

pioglitazone has been researched along with (4-(n-hydroxyamino)-2r-isobutyl-3s-methylsuccinyl)-l-phenylglycine-n-methylamide in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Morimoto, Y; Nishikawa, K; Ohashi, M1

Other Studies

1 other study(ies) available for pioglitazone and (4-(n-hydroxyamino)-2r-isobutyl-3s-methylsuccinyl)-l-phenylglycine-n-methylamide

ArticleYear
KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production.
    Life sciences, 1997, Volume: 61, Issue:8

    Topics: Animals; Blood Glucose; Body Weight; Glycine; Hydroxamic Acids; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metalloendopeptidases; Mice; Mice, Inbred BALB C; Pioglitazone; Protease Inhibitors; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha

1997